Search

Ovid therapeutics Inc

Закрыт

СекторЗдравоохранение

2.91 3.56

Обзор

Изменение цены акций

24 ч

Текущая

Мин.

2.65

Макс.

2.84

Ключевые показатели

By Trading Economics

Доход

2M

-15M

Продажи

733K

733K

Прибыль на акцию

-0.08

Рентабельность продаж

-2,047.476

Сотрудники

23

EBITDA

566K

-16M

Рекомендации

By TipRanks

Рекомендации

Активная покупка

Прогноз на 12 месяцев

+121.63% upside

Дивиденды

By Acuity

Следующий отчет о доходах

11 нояб. 2026 г.

Рыночная статистика

By TradingEconomics

Рыночная капитализация

50M

539M

Предыдущая цена открытия

-0.65

Предыдущая цена закрытия

2.91

Новостные настроения

By Acuity

50%

50%

150 / 340 Рейтинг в Healthcare

Ovid therapeutics Inc График

Прошлые результаты не являются надежным индикатором будущих результатов.

Связанные новости

24 авг. 2026 г., 19:16 UTC

Ovid Therapeutics Inc shares are higher today, recovering from an earlier dip. The stock remains above its 20-day moving average and last month's price.

21 авг. 2026 г., 19:46 UTC

Ovid Therapeutics Inc is trading higher, maintaining a position near its one-month range. Shares pulled back earlier in the session but are advancing overall.

20 авг. 2026 г., 23:31 UTC

Ovid Therapeutics Inc shares are higher in after-market trading, reflecting a significant shift in momentum since Thursday's close. No specific news was identified.

19 авг. 2026 г., 21:21 UTC

Ovid Therapeutics shares declined in after-market trading, finishing near the day's low after peaking earlier in the session. The stock remains above its 20-day moving average.

14 авг. 2026 г., 19:53 UTC

Social Media

Ovid Therapeutics Inc shares are higher as the company advances its clinical pipeline, with key data releases planned through 2026, attracting positive market sentiment.

13 авг. 2026 г., 19:16 UTC

Social Media
News

Ovid Therapeutics reported Q2 EPS of -$0.08, surpassing estimates. Shares are trading higher as the company advances its clinical pipeline and maintains $169.8 million in cash.

12 авг. 2026 г., 19:46 UTC

Ovid Therapeutics Inc shares are higher, supported by positive sentiment from a recent inflation report, despite earlier declines in the session.

7 авг. 2026 г., 19:26 UTC

Ovid Therapeutics Inc shares are lower today amid broader market dynamics. The stock briefly peaked earlier in the session before declining.

6 авг. 2026 г., 22:51 UTC

Ovid Therapeutics Inc. shares are lower in after-market trading, declining since Thursday's close despite remaining above its 20-day moving average.

5 авг. 2026 г., 21:03 UTC

Ovid Therapeutics Inc shares are higher in after-market hours, continuing a positive trend from four consecutive days of gains. No specific news was identified.

4 авг. 2026 г., 23:01 UTC

Ovid Therapeutics Inc shares are lower in after-market trading, with no specific news identified to explain the decline since Tuesday's close.

3 авг. 2026 г., 19:11 UTC

News

Ovid Therapeutics shares are higher as Oppenheimer raises the price target to $9.00 from $7.00, maintaining an Outperform rating.

31 июл. 2026 г., 20:02 UTC

Ovid Therapeutics Inc shares are lower today amid rising Treasury yields and crude oil prices, contributing to broader inflation concerns affecting the biotechnology sector.

27 июл. 2026 г., 20:07 UTC

Ovid Therapeutics Inc shares are higher during Monday's session, following a cumulative gain since Friday. The stock pulled back from earlier session highs.

22 июл. 2026 г., 18:46 UTC

Ovid Therapeutics Inc shares are lower amid broader market volatility linked to rising crude oil prices and geopolitical tensions, with no specific news identified.

20 июл. 2026 г., 19:36 UTC

Ovid Therapeutics Inc shares are lower today, continuing a trend of declines amid broader market pressure from geopolitical tensions and rising oil prices.

Сравнение c конкурентами

Изменение цены

Ovid therapeutics Inc Прогноз

Целевая цена

By TipRanks

121.63% рост

Прогноз на 12 месяцев

Средняя 6.25 USD  121.63%

Максимум 9 USD

Минимум 4 USD

Основано на мнении 6 аналитиков Wall Street, спрогнозировавших целевые цены для Ovid therapeutics Inc на следующие 12 месяцев – Данные за последние 3 месяца.

Консенсус по рейтингу

By TipRanks

Активная покупка

6 ratings

6

Покупка

0

Удержание

0

Продажа

Настроения

By Acuity

150 / 340Рейтинг в Здравоохранение

Новостные настроения

Neutral

Волатильность

Ниже среднего

Объем новостей (RCV)

Ниже среднего

Финансовые показатели

Расходы на продажи и администрирование

Операционные расходы

Прибыль до уплаты налогов

Продажи

Себестоимость реализации

Валовая прибыль от продаж

Процентные расходы по долгу

EBITDA

Операционная прибыль

$

О компании Ovid therapeutics Inc

Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing soticlestat, a novel cholesterol 24 hydroxylase inhibitor, which is in Phase 3 clinical trials for the potential treatment of patients with resistant epilepsies; OV329, a GABA aminotransferase inhibitor which is in Phase 1 clinical trials for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule direct activator of the KCC2 transporter, which is in Phase 1 clinical trials for treating epilepsies. It also develops OV815, that focuses on the mutations associated with KIF1A-associated neurological disorder (KAND); OV888 (GV101), a highly selective rock2 inhibitor which is in Phase 1 double-blind multiple-ascending dose trial; OV825, has advanced to potential candidate lead identification for the rare neurodevelopmental condition HNRNPH2 (Bain Syndrome); and OV882, a short hairpin RNA gene therapy for the treatment of Angelman syndrome. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, Northwestern University, and Graviton, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.
help-icon Live chat